Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Trial in Adult Acute Myeloid Leukemia: Daunorubicin Dose-Intensification Prior to Risk-Allocated Autologous Stem Cell Transplantation
Brief Summary: RATIONALE: Giving combination chemotherapy before a stem cell transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the transplanted stem cells. When the healthy stem cells are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. If the patient's stem cells are to be transplanted, the patient is also treated with a monoclonal antibody, such as gemtuzumab ozogamicin, to kill any remaining cancer cells or deliver cancer-killing substances to them without harming normal cells. It is not yet known whether combination chemotherapy is more effective with or without gemtuzumab ozogamicin followed by stem cell transplant in treating acute myeloid leukemia.

PURPOSE: This randomized phase III trial is studying combination chemotherapy, gemtuzumab ozogamicin, and stem cell transplant to see how well they work compared to combination chemotherapy and peripheral stem cell transplant alone in treating patients with acute myeloid leukemia.


Options:
A: Arm Label: Standard Daunorubicin Then Autologous HCT; Type: EXPERIMENTAL; Interventions: Biological: sargramostim, Drug: busulfan, Drug: cyclophosphamide, Drug: cytarabine, Drug: Daunorubicin, Procedure: Autologous HCT | Arm Label: High-dose Daunorubicin Then Autologous HCT; Type: EXPERIMENTAL; Interventions: Biological: sargramostim, Drug: busulfan, Drug: cyclophosphamide, Drug: cytarabine, Drug: Daunorubicin, Procedure: Autologous HCT | Arm Label: Standard Daunorubicin Then GO/Autologous HCT; Type: EXPERIMENTAL; Interventions: Biological: sargramostim, Drug: busulfan, Drug: cyclophosphamide, Drug: cytarabine, Drug: gemtuzumab ozogamicin (GO), Drug: Daunorubicin, Procedure: Autologous HCT | Arm Label: High-dose Daunorubicin Then GO/Autologous HCT; Type: EXPERIMENTAL; Interventions: Biological: sargramostim, Drug: busulfan, Drug: cyclophosphamide, Drug: cytarabine, Drug: gemtuzumab ozogamicin (GO), Drug: Daunorubicin, Procedure: Autologous HCT | Arm Label: Standard Daunorubicin Then Allogeneic HCT or no Consolidation; Type: ACTIVE_COMPARATOR; Interventions: Drug: cytarabine, Drug: Daunorubicin, Procedure: Allogeneic HCT | Arm Label: High-dose Daunorubicin Then Allogeneic HCT or no Consolidation; Type: EXPERIMENTAL; Interventions: Drug: cytarabine, Drug: Daunorubicin, Procedure: Allogeneic HCT | Intervention Type: BIOLOGICAL; Name: sargramostim; Assigned to Arm(s): High-dose Daunorubicin Then Autologous HCT, High-dose Daunorubicin Then GO/Autologous HCT, Standard Daunorubicin Then Autologous HCT, Standard Daunorubicin Then GO/Autologous HCT | Intervention Type: DRUG; Name: busulfan; Assigned to Arm(s): High-dose Daunorubicin Then Autologous HCT, High-dose Daunorubicin Then GO/Autologous HCT, Standard Daunorubicin Then Autologous HCT, Standard Daunorubicin Then GO/Autologous HCT | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): High-dose Daunorubicin Then Autologous HCT, High-dose Daunorubicin Then GO/Autologous HCT, Standard Daunorubicin Then Autologous HCT, Standard Daunorubicin Then GO/Autologous HCT | Intervention Type: DRUG; Name: cytarabine; Assigned to Arm(s): High-dose Daunorubicin Then Allogeneic HCT or no Consolidation, High-dose Daunorubicin Then Autologous HCT, High-dose Daunorubicin Then GO/Autologous HCT, Standard Daunorubicin Then Allogeneic HCT or no Consolidation, Standard Daunorubicin Then Autologous HCT, Standard Daunorubicin Then GO/Autologous HCT | Intervention Type: DRUG; Name: gemtuzumab ozogamicin (GO); Assigned to Arm(s): High-dose Daunorubicin Then GO/Autologous HCT, Standard Daunorubicin Then GO/Autologous HCT | Intervention Type: DRUG; Name: Daunorubicin; Assigned to Arm(s): High-dose Daunorubicin Then Allogeneic HCT or no Consolidation, High-dose Daunorubicin Then Autologous HCT, High-dose Daunorubicin Then GO/Autologous HCT, Standard Daunorubicin Then Allogeneic HCT or no Consolidation, Standard Daunorubicin Then Autologous HCT, Standard Daunorubicin Then GO/Autologous HCT | Intervention Type: PROCEDURE; Name: Autologous HCT; Assigned to Arm(s): High-dose Daunorubicin Then Autologous HCT, High-dose Daunorubicin Then GO/Autologous HCT, Standard Daunorubicin Then Autologous HCT, Standard Daunorubicin Then GO/Autologous HCT | Intervention Type: PROCEDURE; Name: Allogeneic HCT; Assigned to Arm(s): High-dose Daunorubicin Then Allogeneic HCT or no Consolidation, Standard Daunorubicin Then Allogeneic HCT or no Consolidation
B: Arm Label: Cytarabine low dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cytarabine | Arm Label: Cytarabine intermediate dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cytarabine | Intervention Type: DRUG; Name: Cytarabine; Assigned to Arm(s): Cytarabine intermediate dose, Cytarabine low dose
C: Intervention Type: DRUG; Name: Cytarabine vs. Cytarabine+Amsacrine+Mitoxantrone; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: early allogeneic PBSCT within induction therapy; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: autologous PBSCT; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Idarubicin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Cytosin-Arabinosid; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Etoposide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: All-trans Retinoid acid; Assigned to Arm(s): N/A

Answer: A